Connecticut Department Of Public Health Urges Residents To Consider Their Health When Choosing A New Year’s Resolution
The Connecticut Department of Public Health (DPH) is urging people to consider resolutions for a healthy lifestyle for the New Year. Whether your resolution is to take better care of your general health, lose weight, or quit using tobacco, the DPH offers tips and resources to help you succeed in leading a healthier lifestyle.
Chronic diseases are responsible for 7 out of 10 deaths in the United States, and lead to pain, disability and decreased quality of life for millions of Americans – yet they are also among the most preventable of all health problems. In July, Governor M. Jodi Rell announced the availability of an online, interactive tool to help improve the health, fitness and quality of life of Connecticut residents. Developed with funding from a grant awarded by the National Governors’ Association, the Protective Health Assessment, or PHA, is available at www.dph-ct.us and focuses on the prevention and early detection of chronic diseases and their related risk factors.
“The Protective Health Assessment is a great tool for people to use to evaluate their health and help them on the road to a healthy life,” stated DPH Commissioner J. Robert Galvin. “The confidential, online assessment only takes 10-15 minutes to complete and will give you a personalized report about your health habits as well as give recommendations on how to reduce or better manage your risk for chronic disease.”
The Centers for Disease Control and Prevention (CDC) estimates that 66.3% of adult Americans are considered overweight or obese, so it’s not surprising that weight loss is at the top of many New Year’s resolution lists. Healthy weight loss isn’t just about diet or a program, but rather making a commitment to an overall healthy lifestyle regarding daily eating and physical activity habits. Evidence shows that people who lose weight gradually and steadily (about 1 to 2 pounds per week) are more successful at keeping and maintaining weight off.
“Being overweight can contribute to other health problems including diabetes, heart disease and even asthma,” said Commissioner Galvin. “Establishing and maintaining a healthy weight will make you feel much better inside and out. We understand that sometimes it’s hard to get there, but once you reach your goal, you will much improve your quality of life.”
If you are ready to take the challenge, here are some tips from the Connecticut Department of Public Health on getting started:
– Write it down and make a plan that includes the amount of weight you want to lose, the date you’d like to lose the weight by, the dietary changes you’ll make to establish healthy eating habits, and a plan for getting regular physical activity.
– Before you start your new healthy lifestyle, consider meeting with your health care provider to assess your height, weight, and explore other weight-related risk factors you may have, and schedule a follow-up to monitor any changes. Keep a diary and identify any barriers to healthy eating and being physically active and plan solutions to overcome them.
– Be realistic and set achievable goals so you don’t get discouraged. Small changes in the beginning can lead to big results in the long run and serve as positive motivation to keep going!
– Use the “buddy system.” Family members, friends, coworkers or neighbors with similar goals can be great support and make the healthy lifestyle changes easier.
– Monitor and evaluate your goals and progress continually, and adjust or change as necessary. Once a goal is achieved, add a new one to keep your healthy lifestyle fresh and to help you continue on your pathway to success.
Quitting tobacco use is another great way to improve your health. More than 450,000 adults in Connecticut are cigarette smokers, and every year in Connecticut, more than 4,900 people die from smoking-related diseases. To assist smokers in their attempt to quit, the following resources are available free of charge in Connecticut.
– The Connecticut QuitLine at 1-866-END-HABIT (1-866-363-4224) is available to all Connecticut residents from 8 AM to 3 AM seven days a week. By calling the QuitLine for help, professionally trained Quit Coaches will help to prepare participants for their quit date and help them to design their own quit plan. Many of the Quit Coaches are former smokers themselves.
– The BecomeAnEX.org website offers an online support service that allows tobacco users to create their own quit plan, blog with other users, and ask questions of professionals. Log on to www.BecomeAnEX.org to start.
– Six community health centers have been funded to provide tobacco cessation programs to pregnant women and women of childbearing age (13-44): Community Health Center, Inc., Middletown; Fair Haven Community Health Clinic, Inc., New Haven; Generations Family Health Center, Inc., Willimantic; Hill Health Corporation, New Haven; Optimus Health Care, Inc., Bridgeport, and StayWell Health Care, Inc., Waterbury. The programs include educational materials, counseling, and quit medications if appropriate.
Setbacks happen for a variety of reasons, don’t let them deter you and remember to reward yourself occasionally for meeting your goals and to help keep you motivated on the path to better health!
The Connecticut Department of Public Health is the state’s leader in public health policy and advocacy with a mission to protect and promote the health and safety of the people of our state. To contact the department, please visit its website at http://www.ct.gov/dph.
Department Promoting Early Substance Use Screening Process
The Wyoming Department of Health is strengthening its promotion of early screening for substance use-related health issues by reimbursing Wyoming healthcare providers who participate through its EqualityCare (Medicaid) program.
Known as Screening, Brief Intervention and Referral to Treatment (SBIRT), the simple screening process involves just a few questions. Trained interviewers work with individuals to determine their risk level based upon behavior patterns. A brief educational intervention can significantly reduce or even end the person’s use of harmful substances. For those whose screening indicates a severe problem or dependence, the next step is referral to Wyoming community mental health and substance abuse centers.
“Many people don’t realize how their use of legal and illegal substances may impact their health,” said Rodger McDaniel, Wyoming Department of Health deputy director for mental health and substance abuse services. “The goal is to educate before addiction sets in.”
Research has shown that large numbers of individuals at risk of developing serious alcohol or other drug problems may be identified through primary care screening.
“We want to involve Wyoming healthcare providers because screening in a medical setting can be particularly successful. The focus is on a person’s health rather than appearing as a judgment on behaviors, and the patient controls how much information they want to receive,” McDaniel said.
McDaniel expects SBIRT to eventually save the state money. “When you are able to intervene early with nondependent users before dependence has taken hold, you can decrease expensive substance abuse treatment costs, reduce hospital stays and see fewer emergency department visits.”
Last year the Wyoming Department of Health began encouraging the practice around Wyoming in medical settings in places such as the Cheyenne Free Clinic, certain public health nursing offices and the Laramie County public defender’s office.
Participating EqualityCare (Medicaid) providers are being notified of the new SBIRT billing code opportunities. Teri Green, State Medicaid Agent, encourages providers to begin impementing SBIRT in their health care settings. “The SBIRT process supports prevention and wellness. This is an excellent tool for provider to use to promote quality outcomes to the citizens of Wyoming, ” said Teri Green. EqualityCare will begin covering SBIRT HCPCS codes H0049 & H0050 with dates of service beginning January 1, 2009, with training planned around the state. Initial training opportunities are expected in Rawlins, Rock Springs, Lander, Jackson, Riverton, Cheyenne and Casper.
For more information about SBIRT, contact the Mental Health and Substance Abuse Services Division at (307) 777-7071. Rembember, commit to your health and the health of others.
http://wdh.state.wy.us
CXCL1 Decreases Severity Of Multiple Sclerosis-like Disease
A group led by Dr. Cedric Raine at Albert Einstein College of Medicine have explored the expression of an immune molecule (CXCL1) that interacts with myelin-producing cells, finding that CXCL1 decreases the severity of disease in a mouse model of multiple sclerosis (MS). They report their data in the January 2009 issue of The American Journal of Pathology.
The autoimmune disease multiple sclerosis (MS) attacks the central nervous system, resulting in demyelination of neurons. Myelin-producing cells in the central nervous system are severely depleted in lesions in patients with MS.
Myelin-producing cells express immune receptors and have been shown to respond to the immune molecule CXCL1, although the role of CXCL1 in MS has not been previously explored. Dr. Raine and colleagues examined the effects of CXCL1 specifically expressed in the nervous system in a mouse model of MS. They observed decreased severity of disease and more prominent remyelination in these mice. CXCL1, therefore, may play a neuroprotective role in CNS autoimmune demyelination.
In future studies, Dr. Raine’s group plans to determine how CXCL1 mediates protection in MS. “Exploration of these pathways affords novel therapeutic avenues to enhance the limited remyelination typically seen in MS.”
Omari KM, Lutz SE, Santambrogio L, Lira SA, Raine CS
“Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1.”
Am J Pathol 2009, 174:164-176
American Journal of Pathology, official journal of the American Society for Investigative Pathology, seeks to publish high-quality, original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.
Source
Angela Colmone
American Journal of Pathology
New Candidate To Prevent Inflammation
Dr. Sonia Oliani and colleagues at São Paulo State University have identified a potential new molecule that inhibits inflammation, receptor for formylated peptides-2 (FPR-2). These findings are presented in the January 2009 issue of The American Journal of Pathology.
Inflammation of the peritoneum is characterized by severe abdominal pain. This inflammation can be prevented by annexin A1, which inhibits the migration of inflammation-inducing white blood cells into the affected area.
In this study, Gastardelo et al examined the identities of the receptors responsible for the anti-inflammatory effects of annexin A1 in a mouse model of peritonitis. FPR family members had been previously shown to interact with annexin A1. Yet FPR-1-deficient mice, unlike annexin A1-null mice, did not have increased white blood cell recruitment. Instead, annexin A1 colocalized with another FPR family member, FPR-2.
The data by Gastardelo et al “provide in vivo evidence that endogenous annexin A1 is an essential mediator for homeostasis during the inflammatory process.” They go on to propose “that these experimental findings may impact the development of novel therapeutics based on the anti-migratory actions of annexin A1.”
Gastardelo TS, Damazo AS, Dalli J, Flower RJ, Perretti M, Oliani SM
“Functional and ultrastrutural analysis of annexin A1 and its receptor in extravasting neurophils during inflammation.
Am J Pathol 2009, 174:177-183
American Journal of Pathology, official journal of the American Society for Investigative Pathology, seeks to publish high-quality, original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.
Source
Angela Colmone
American Journal of Pathology
Cyclophilin B Is A Possible New Target For Treating Breast Cancer
Dr. Charles Clevenger and colleagues at Northwestern University have uncovered that cyclophilin B may contribute to progression in breast cancer. Their report can be found in the January 2009 issue of The American Journal of Pathology.
The protein cyclophilin B affects cell division, motility, and death, all of which are altered in cancerous cells. To explore the role of cyclophilin B-mediated gene regulation in breast cancer, Dr. Clevenger and colleagues inhibited cyclophilin B expression in breast cancer cells. They found that absence of cyclophilin B impacted 27 different protein networks and decreased cell proliferation, motility, and tumorigenesis. In addition, in human breast tissue, increases in cyclophilin B protein levels correlated with the presence of breast cancer metastases.
The studies by Fang et al “demonstrate that a decrease in cyclophilin B levels .. can profoundly alter the expression of genes and cellular functions relevant to the pathogenesis and progression of breast cancer. In this regard, the development of additional pharmacologic agents that specifically target each of the cyclophilins may have significant utility in the treatment of this disease.”
Fang F, Flegler AJ, Du P, Lin S, Clevenger CV
“Expression of Cyclophilin B is Associated with Malignant Progression and Regulation of Genes Implicated in the Pathogenesis of Breast Cancer.”
Am J Pathol 2009, 174:297-308
American Journal of Pathology, official journal of the American Society for Investigative Pathology, seeks to publish high-quality, original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.
Source
Angela Colmone
American Journal of Pathology
Inflammation Contributes To Colon Cancer
Researchers led by Dr. Brian Iritani at The University of Washington found that mice that lack the immune inhibitory molecule Smad3 are acutely sensitive to both bacterially-induced inflammation and cancer. They report these findings in the January 2009 issue of The American Journal of Pathology.
Bacteria contribute to the development of certain cancers, in some measure, by stimulating chronic inflammation. Absence of a molecule that inhibits inflammation, Smad3, may therefore increase susceptibility to colon cancer.
To examine whether Smad3 signaling contributes to development of colon cancer, Maggio-Price et al examined mice deficient in Smad3 that lack of adaptive immune responses. They found that these mice are acutely sensitive to bacterially-induced inflammation and cancer due to both deficient T regulatory cell function and increased expression of proinflammatory cytokines. Through increased expression of both pro-oncogenic and anti-apoptotic proteins, epithelial cells in colonic tissues underwent both enhanced proliferation and survival.
“That the inflammatory response to microorganisms is a key event in these results reveals important ‘tumor-suppressive’ functions for Smad3 in T effector cells, T regulatory cells, and intestinal epithelial cells, all of which may normally limit the development of colon cancer in response to bacterial inflammation,” explains Dr. Iritani’s group.
Maggio-Price L, Treuting P, Bielefeldt-Ohmann H, Seamons A, Drivdahl R, Zeng W, Lai L-H, Huycke M, Phelps S, Brabb T1, Iritani BM
“Bacterial infection of Smad3/Rag2 double-null mice with TGF beta dysregulation as a model for studying inflammation-associated colon cancer.
Am J Pathol 2009, 174:317-329
American Journal of Pathology, official journal of the American Society for Investigative Pathology, seeks to publish high-quality, original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.
Source
Angela Colmone
American Journal of Pathology
Colorado QuitLine Offers Tobacco Users Hundreds Of Dollars In Valuable Service And Product To Quit For The New Year
As the new year approaches, thousands of tobacco users have “quit” on their New Year’s resolution list. But studies show that those who want to quit find it more difficult in times of stress, such as the current economic downturn. The Colorado QuitLine provides tobacco users with a free telephone coaching service and a free supply of the nicotine patch – valued at approximately $300.
Financial stress can be a key smoking trigger. According to a study sponsored by the American Legacy Foundation, 77 percent of current smokers report increased stress levels due to the current state of the economy, and two-thirds of those smokers say this stress has had an effect on their smoking.
“With the uncertainty of the economic landscape and concerns about job security, tobacco users need comprehensive resources that tackle their tobacco addiction,” said Deb Montgomery Osborne, State Tobacco Education & Prevention Partnership’s director of tobacco cessation initiatives. “The Colorado QuitLine gives people a valuable service that has been proven to work.”
Quitting also can save the average Colorado smoker $1,800 per year. This assistance, along with tapping into Colorado QuitLine’s free customized coaching sessions and free supply of the patch, can add up to worthwhile savings. Dr. David Tinkelman, vice president of health initiatives at National Jewish Health, said, “It’s important for people to see the economic value in what they’re doing, but it’s just as important for people to understand that they’ll experience immediate health benefits as well. Smokers’ immune systems will improve immediately, and this means they’ll have the ability to breathe easier and fight colds – particularly during the winter season when germs spread more easily.”
Other immediate health benefits of quitting include increased energy, improved circulation, decreased blood pressure and heart rate, and improved senses of taste and smell. The long-term benefits include decreasing the risk of chronic diseases and increasing the life span by 5 to 12 years.
Cigarette smoking is the leading cause of preventable deaths in the United States. About 4,300 Coloradans die every year from tobacco-related illnesses. Smoking leads to severe health problems – including cancer, heart disease and strokes. Additionally, research shows that secondhand smoke is a known cause of lung cancer, heart disease and chronic lung ailments, such as bronchitis and asthma. Annual Colorado health-care costs directly caused by tobacco use exceed $1.3 billion.
Those who want to quit or those who are thinking about quitting can seek help and support from the Colorado QuitLine – a free telephone coaching service for quitting tobacco that offers a free supply of the patch. To contact the QuitLine, call 1-800-QUIT-NOW (1-800-784-8669) or visit http://www.coquitline.org for Web-based cessation tools. The Colorado QuitLine is operated by National Jewish Health under contract to the State Tobacco Education & Prevention Partnership at the Colorado Department of Public Health and Environment. QuitLine coaches are available Mondays through Fridays, 7 a.m. to 9 p.m., and Saturdays and Sundays, 8 a.m. to 4:30 p.m.
The Prevalence Of Gluten-sensitive Enteropathy In Iron-deficient Anemia Patients
Gluten sensitive enteropathy (GSE) is an autoimmune enteropathy due to food gluten intolerance in genetically predisposed people. While GSE was thought to be a rare disease in the past and was believed to be essentially a disease of Europeans, recent screening studies showed that GSE is one of the most frequent genetically based diseases occured worldwide. Iron deficiency anemia could be a sole manifestation of GSE, and it might result in the delayed diagnosis of GSE, resulting in complications.
A research team led by Prof. Reza Malekzadeh studied the prevalence of gluten sensitive enteropathy (GSE) in a large group of patients with iron deficiency anemia (IDA) of obscure origin. Their findings will be published on December 28, 2008 in the World Journal of Gastroenterology.
In this prospective study, 4120 patients with IDA were enrolled in this study. Anti-endomysial antibody (EMA) and tissue transglutaminase antibody (tTG) levels were evaluated and duodenal biopsies were taken and scored according to the Marsh classification. The diagnosis of GSE was based on a positive serological test and abnormal duodenal histology. Gluten free diet (GFD) was advised for all the GSE patients.
Of the 4 120 IDA patients, 206 (95 male) patients were found to have IDA of obscure origin. Thirty out of 206 patients (14.6%) had GSE. Sixteen patients had Marsh 3, 12 had Marsh 2, and 2 had Marsh 1 lesions. The severity of anemia was in parallel with the severity of duodenal lesions. Twenty-two GSE patients (73.3%) had no gastrointestinal symptoms. Fourteen GSE patients who adhered to GFD without receiving iron supplementation agreed to undergo follow up visits. After 6 mo of GFD, their mean hemoglobin levels (Hb) increased from 9.9 ± 1.6 to 12.8 ± 1.0 g/dL (P
—————————-
Article adapted by Medical News Today from original press release.
—————————-
Reference: Zamani F, Mohamadnejad M, Shakeri R, Amiri A, Najafi S, Alimohamadi SM, Tavangar SM, Ghavamzadeh A, Malekzadeh R. Gluten sensitive enteropathy in patients with iron deficiency anemia of unknown origin. World J Gastroenterol 2008; 14(48): 7381-7385 www.wjgnet.com/1007-9327/14/7381.asp
About World Journal of Gastroenterology
World Journal of Gastroenterology (WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H pylori infection and provides a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2003-2000 IF: 3.318, 2.532, 1.445 and 0.993. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th day of every month. WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the name of China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.
About The WJG Press
The WJG Press mainly publishes World Journal of Gastroenterology
.
Lai-Fu Li
World Journal of Gastroenterology
Is Bismuth A Safe Medicine For The Treatment Peptic Ulcer Disease?
Bismuth compounds have been used for centuries in medicine. The discovery of H. pylori in 1983 led to renewed interest in bismuth compounds, because these were found to successfully treat the infection in combination with antibiotics. However, in the 1970s bismuth salts, used at high doses for prolonged periods, were found to lead to neurotoxicity. There has been no summary of evidence for the toxicity of bismuth when used for short periods as part of H. pylori eradication therapy.
A research article to be published on December 28, 2008 in the World Journal of Gastroenterology addresses this question. The research team led by Professor Paul Moayyedi from McMaster University, Canada performed a systematic review and meta-analysis to assess the safety of bismuth compounds, when used in a 1 or 2-week course of H. pylori eradication therapy. They examined the risk of adverse events in randomized controlled trials using bismuth compounds as part of H. pylori eradication therapy compared to other regimens.
Thirty-five randomized controlled trials containing over 4500 patients were identified comparing bismuth with placebo or no treatment, or bismuth salts in combination with antibiotics as part of eradication therapy with the same dose and duration of antibiotics alone or in combination with acid suppression. There were no differences in the total number of adverse events with bismuth versus comparison regimen. Individual adverse events were also no more frequent with bismuth, with the exception of dark stools. There were no significant differences detected in the number of adverse events leading to withdrawal of therapy with bismuth versus comparison regimen.
Their results indicated that Bismuth compounds, when used as part of H. pylori eradication therapy, are safe and well-tolerated. The only adverse event occurring more frequently with bismuth compounds was dark stools, which is of little clinical significance.
These results are encouraging, because there have been recent concerns expressed that PPI-based triple therapies for H. pylori do not lead to satisfactory eradication rates, and therefore the use of bismuth containing regimens has been recommended as a potential first line therapy in the recent Maastricht guidelines. Furthermore, there are now new bismuth combinations commercially available. For these reasons it is important to be sure of the safety of bismuth compounds.
—————————-
Article adapted by Medical News Today from original press release.
—————————-
Reference: Ford AC, Malfertheiner P, Giguère M, Santana J, Khan M, oayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: Systematic review and meta-analysis. World Gastroenterol 2008; 14(48): 7361-7370 www.wjgnet.com/1007-9327/14/7361.asp
About World Journal of Gastroenterology
World Journal of Gastroenterology (WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H pylori infection and provides a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2003-2000 IF: 3.318, 2.532, 1.445 and 0.993. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th day of every month. WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the name of China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.
About The WJG Press
The WJG Press mainly publishes World Journal of Gastroenterology
.
Lai-Fu Li
World Journal of Gastroenterology
What Is The Pathogenesis Of C. Jejuni-related Disease?
Campylobacters are small Gram-negative spiral rods. Campylobacter jejuni (C. jejuni), a foodborne organism contracted from untreated water, milk and meat, especially chicken, is one of the most important causes of bacterial diarrhea worldwide. However, its mode of pathogenesis is not clear.
A research article to be published on December 28, 2008 in the World Journal of Gastroenterology addresses this question. The research team led by Christopher J Hawkey from Nottingham University Hospital of United Kingdom investigated whether different strains isolated from patients with Campylobacter infection had different effects.
Nineteen consecutive strains from community patients with acute bacterial enteritis were isolated and three of them were compared with the laboratory strain 12189. All strains translocated across monolayers but only a minority invaded HCA-7 cells. Strains that invaded HCA-7 cells destroyed monolayer resistance over 6 h, accompanied by increased release of lactate. dehydrogenase, a four-fold increase in permeability to (3H) mannitol, and ultrastructural disruption of tight junctions, with rounding and lifting of cells off the filter membrane. Synthesis of interleukin (IL)-8 and prostaglandin E2 was increased with strains that invaded the monolayer but not with those that did not.
Their results indicated that two distinct patterns of interaction between clinical isolates of C. jejuni and a colonic epithelial cell line. Strains that invaded epithelial cells were shown to destroy them, Strains that did not invade epithelial cells did not affect barrier properties or increase mediator production. The data raised the possibility that with some Campylobacter infections the epithelian can be the source of pro-secretory and pro-inflammatory compounds.
—————————-
Article adapted by Medical News Today from original press release.
—————————-
Reference: Beltinger J, del Buono J, Skelly MM, Thornley J, Spiller RC, Stack WA, Hawkey CJ. Disruption of colonic barrier function and induction of mediator release by strains of Campylobacter jejuni that invade epithelial cells. World J Gastroenterol 2008; 14(48): 7345-7352 www.wjgnet.com/1007-9327/14/7345.asp
About World Journal of Gastroenterology
World Journal of Gastroenterology (WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H pylori infection and provides a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2003-2000 IF: 3.318, 2.532, 1.445 and 0.993. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th day of every month. WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the name of China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.
About The WJG Press
The WJG Press mainly publishes World Journal of Gastroenterology
.
Lai-Fu Li
World Journal of Gastroenterology
leave a comment